• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项单中心试验中治疗效果可重复性的证明。

Demonstration of the reproducibility of treatment efficacy from a single multicenter trial.

作者信息

Huster W J, Louv W C

机构信息

Biostatistics Department, Marion Merrell Dow Research and Development, Cincinnati, Ohio 45215.

出版信息

J Biopharm Stat. 1992;2(2):219-38. doi: 10.1080/10543409208835041.

DOI:10.1080/10543409208835041
PMID:1300215
Abstract

According to the Food and Drug Administration's Guidelines for the Format and Content of the Clinical and Statistical Sections of New Drug Applications, approval of a new drug "should be supported by more than one well-controlled trial and carried out by independent investigators. This interpretation is consistent with the general scientific demand for replicability." Nevius has described a four-point proposal for assessing statistical evidence in a single multicenter trial. Briefly, these four points are: (1) combined analysis shows significant results, (2) consistency over centers in terms of direction, (3) consistency over centers in terms of producing nominally significant results in centers with sufficient power, and (4) evidence of efficacy after adjustment for multiple comparisons. What is not clear from Nevius' proposal is how to quantify whether the amount of evidence in a single multicenter trial is equivalent to that from two separate trials. It is proposed that the post hoc subdivision of a multicenter trial may address this issue if the inherent multiple testing problem is accommodated. A minimax statistic is developed to test the hypothesis that the effect of the drug has been reproduced in a single multicenter trial. Monte Carlo simulation is used to generate the distribution of the minimax statistic under the null and several alternative hypotheses. Data from a multicenter trial are used to demonstrate the technique. Bootstrapping is used to determine the null distribution of the minimax statistic.

摘要

根据美国食品药品监督管理局关于新药申请临床和统计部分格式与内容的指南,新药的批准“应有不止一项严格对照试验的支持,且由独立研究者进行。这种解释与对可重复性的一般科学要求一致。”内维斯描述了一项在单一多中心试验中评估统计证据的四点提议。简而言之,这四点是:(1)合并分析显示显著结果;(2)各中心在方向上一致;(3)各中心在有足够检验效能的中心产生名义上显著结果方面一致;(4)经多重比较调整后的疗效证据。内维斯的提议中不明确的是如何量化单一多中心试验中的证据量是否等同于两项单独试验的证据量。有人提出,如果能解决固有的多重检验问题,多中心试验的事后细分可能会解决这个问题。开发了一种极小极大统计量来检验药物效应在单一多中心试验中是否重现的假设。蒙特卡罗模拟用于生成在原假设和几个备择假设下极小极大统计量的分布。来自一项多中心试验的数据用于演示该技术。使用自助法来确定极小极大统计量的原分布。

相似文献

1
Demonstration of the reproducibility of treatment efficacy from a single multicenter trial.一项单中心试验中治疗效果可重复性的证明。
J Biopharm Stat. 1992;2(2):219-38. doi: 10.1080/10543409208835041.
2
Testing for consistency in a single multicenter trial.
J Biopharm Stat. 1991;1(1):67-80. doi: 10.1080/10543409108835006.
3
Lessons learned from independent central review.独立中央审查的经验教训。
Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.
4
Test homogeneity of odds ratio in a randomized clinical trial with noncompliance.在存在不依从性的随机临床试验中检验比值比的同质性。
J Biopharm Stat. 2009 Sep;19(5):916-32. doi: 10.1080/10543400903105497.
5
Pemetrexed in malignant pleural mesothelioma.培美曲塞用于恶性胸膜间皮瘤
Clin Cancer Res. 2005 Feb 1;11(3):982-92.
6
Analysis of homogeneity of treatment effect in adaptive multicenter clinical trials.适应性多中心临床试验中治疗效果的同质性分析。
J Biopharm Stat. 1998 Mar;8(1):55-67. doi: 10.1080/10543409808835222.
7
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.美国食品药品监督管理局批准摘要:硼替佐米用于治疗经过一种既往疗法后的进展性多发性骨髓瘤。
Clin Cancer Res. 2006 May 15;12(10):2955-60. doi: 10.1158/1078-0432.CCR-06-0170.
8
Estimation of the treatment difference in multicenter trials.多中心试验中治疗差异的估计。
J Biopharm Stat. 2004 Nov;14(4):1037-63. doi: 10.1081/BIP-200035487.
9
[Controlled randomized clinical trials].[对照随机临床试验]
Bull Acad Natl Med. 2007 Apr-May;191(4-5):739-56; discussion 756-8.
10
Reproducibility probability in clinical trials.临床试验中的可重复性概率。
Stat Med. 2002 Jun 30;21(12):1727-42. doi: 10.1002/sim.1177.

引用本文的文献

1
Multiplexed methylation profiles of tumor suppressor genes in bladder cancer.膀胱癌中肿瘤抑制基因的多重甲基化谱。
J Mol Diagn. 2011 Jan;13(1):29-40. doi: 10.1016/j.jmoldx.2010.11.008. Epub 2010 Dec 23.
2
The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.跨国成本效益数据分析在报销决策中的应用:对近期方法学发展的批判性评价。
Pharmacoeconomics. 2010;28(12):1079-96. doi: 10.2165/11537760-000000000-00000.